Effects of Blood Pressure Level on Progression of Diabetic Nephropathy Results From the RENAAL Study
2003/07/14 by George L. Bakris · 26 citations
Medicine · #Blood Pressure and Hypertension Studies #Renin-Angiotensin System Studies #Hormonal Regulation and Hypertension
paper · doi:10.1001/archinte.163.13.1555
Abstract
BACKGROUND: Clinical trials of nephropathy in people with type 2 diabetes mellitus have not examined the effects of systolic blood pressure (SBP) or pulse pressure (PP) on the time to end-stage renal disease (ESRD) or death. OBJECTIVES: To evaluate the impact of baseline and treated SBP, diastolic blood pressure (DBP), and PP on composite and individual outcomes including doubling of serum creatinine, ESRD, or death in participants of the Reduction of Endpoints in NIDDM (non-insulin-dependent diabetes mellitus) With the Angiotensin II Antagonist Losartan (RENAAL) Study; to assess the specific effect of the angiotensin receptor blocker losartan potassium on composite and renal outcomes; and to explore the implications of dihydropyridine calcium channel blockers as concurrent therapy on composite and renal outcomes. DESIGN: A Cox proportional hazards regression model was used to assess the hazard risk profile of baseline SBP (categories: <130, 130-139, 140-159, 160-179, and > or =180 mm Hg), DBP (categories: <70, 70-79, 80-89, 90-99, and > or =100 mm Hg), and PP (categories: <60, 60-69, 70-79, 80-89, and > or =90 mm Hg) on renal outcomes. PARTICIPANTS: The study comprised 1513 participants with established nephropathy and hypertension associated with type 2 diabetes. INTERVENTIONS: The RENAAL study was a randomized, placebo-controlled study of losartan vs placebo, with other agents added to achieve the goal of a trough BP (ie, BP immediately prior to the next dosing) below 140/90 mm Hg, and had a mean follow-up of 3.4 years. MAIN OUTCOME MEASURES: The primary analysis was time to composite end point of doubling of serum creatinine, ESRD, or death. RESULTS: A baseline SBP range of 140 to 159 mm Hg increased risk for ESRD or death by 38% (P =.05) compared with those below 130 mm Hg. In a multivariate model, every 10-mm Hg rise in baseline SBP increased the risk for ESRD or death by 6.7% (P =.007); the same rise in DBP decreased the risk by 10.9% (P =.01) when adjusting for urinary albumin-creatinine ratio, serum creatinine, serum albumin, hemoglobin, and hemoglobin A1c. Those randomized to the losartan group with a baseline PP above 90 mm Hg had a 53.5% risk reduction for ESRD alone (P =.003) and a 35.5% risk reduction for ESRD or death (P =.02) compared with the placebo group. CONCLUSIONS: Baseline SBP is a stronger predictor than DBP of renal outcomes in those with nephropathy resulting from type 2 diabetes. Those with the highest baseline PP have the highest risk for nephropathy progression but also garner the greatest risk reduction with SBP lowered to less than 140 mm Hg.
Citations
Cited by
- 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension
- Microalbuminuria in type 2 diabetics: an important, overlooked cardiovascular risk factor. [europepmc]
- Progression of kidney disease in type 2 diabetes - beyond blood pressure control: an observational study. [europepmc]
- State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension. [europepmc]
- Lowering blood pressure reduces renal events in type 2 diabetes. [europepmc]
- Racial differences in incident heart failure among young adults. [europepmc]
- Blood pressure components and the risk for end-stage renal disease and death in chronic kidney disease. [europepmc]
- Age, race, diabetes, blood pressure, and mortality among hemodialysis patients. [europepmc]
- Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management. [europepmc]
- Angiotensin II type 1A receptors in vascular smooth muscle cells do not influence aortic remodeling in hypertension. [europepmc]
- Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy. [europepmc]
- Limitations of analyses based on achieved blood pressure: lessons from the African American study of kidney disease and hypertension trial. [europepmc]
- Hemodynamic correlates of proteinuria in chronic kidney disease. [europepmc]
- Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP). [europepmc]
- Blood pressure indexes and end-stage renal disease risk in adults with chronic kidney disease. [europepmc]
- Normoalbuminuric diabetic kidney disease in the U.S. population. [europepmc]
- Kidney function decline in metformin versus sulfonylurea initiators: assessment of time-dependent contribution of weight, blood pressure, and glycemic control. [europepmc]
- BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial. [europepmc]
- Mechanistic Insight and Management of Diabetic Nephropathy: Recent Progress and Future Perspective. [europepmc]
- Diabetic Kidney Disease: Challenges, Progress, and Possibilities. [europepmc]
- Diabetic Nephropathy: a Tangled Web to Unweave. [europepmc]
- Segmental Sclerosis and Extracapillary Hypercellularity Predict Diabetic ESRD. [europepmc]
- Acute Kidney Injury and Progression of Diabetic Kidney Disease. [europepmc]
- Effect of canagliflozin on nocturnal home blood pressure in Japanese patients with type 2 diabetes mellitus: The SHIFT-J study. [europepmc]
- Patient and disease characteristics of type-2 diabetes patients with or without chronic kidney disease: an analysis of the German DPV and DIVE databases. [europepmc]
- Wide pulse pressure: A clinical review. [europepmc]
Related